Skip to main content

Table 1 Population characteristics at baseline

From: Self-perceived ability to cope with stress and depressive mood without smoking predicts successful smoking cessation 12 months later in a quitline setting: a secondary analysis of a randomized trial

  Total Responders Non-responders
Gender: women (% n/N) 77 (474/612) 77 (278/359) 77 (196/253)
Age groups, years (% n/N)
  ≤ 34 20 (122/602) 16 (57/352) 26 (65/250)a
 35–49 25 (150/602) 24 (85/352) 6 (65/250)
 50–64 38 (231/602) 41 (146/352) 34 (85/250)
  ≥ 65 16 (99/602) 18 (64/352) 14 (35/250)
Number of years of education (md, q1-q3, N) 12, 10–13, 594 12, 9–14, 355 12, 10–13, 239
Number of smoked cigarettes/day (data journal) (md, q1-q3, N) 10, 0–20, 505 8, 0–15, 297 11, 3–20, 208a
No smoking in the week before baseline (% n/N) 28 (171/609) 34 (121/359) 20 (50/250)a
Number of years smoked before baseline (md, q1-q3, N) 32, 17–40, 575 35, 20–43, 344 30, 15–40, 231a
Snus use the week before baseline (% n/N) 7 (38/552) 6 (18/318) 9 (20/234)
Exposed to passive smoking (baseline) (% n/N) 26 (147/573) 22 (74/336) 31 (73/237) a
Drug use (NRT, Zyban®, Champix®) the week before baseline (% n/N) 52 (308/592) 57 (198/349) 45 (110/243) a
Other support at baseline (% n/N) 71 (428/600) 73 (254/349) 69 (174/251)
Likelihood of being smoke-free in 1 year (baseline, 1–10) (md, q1-q3, N) 8, 7–10, 590 9, 7–10, 347 8, 7–10, 243
Handle stress and depression successfully without smoking (baseline, 1–10) (md, q1-q3, N) 7, 4–9, 590 7, 4–9, 346 6, 4–8, 244 a
Will use pharmaceuticals if necessary (baseline,1–10) (md, q1-q3, N) 10, 5–10, 592 10, 5–10, 348 9, 5–10, 244
  1. aStatistically significant difference between responders and non-responders. Tested by Chi-2/Fisher’s Exact test or Mann-Whitney U-test